^




Show legend
Group by Gene:
Include preclinical:

Mvasi (bevacizumab biosimilar)
Aybintio (bevacizumab biosimilar)
0
VEGF-A inhibitor
Zirabev (bevacizumab biosimilar)
Bevax (bevacizumab biosimilar)
Krabeva (bevacizumab biosimilar)
bevacizumab
cabozantinib tablet
1
Multi-tyrosine kinase inhibitor
pazopanib
cabozantinib capsule
nivolumab
pembrolizumab
2
PD1 inhibitor
dostarlimab
toripalimab
PD1 inhibitor
everolimus
3
mTOR inhibitor
temsirolimus
sirolimus
mTOR inhibitor
4
IFNα stimulant, VEGF-A inhibitor
bevacizumab + pegylated interferon α -2a
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
5
VEGFR inhibitor, PD1 inhibitor
pembrolizumab + axitinib
6
PD1 inhibitor, Multi-tyrosine kinase inhibitor
nivolumab + cabozantinib tablet
7
PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab
8
c-MET inhibitor
savolitinib
c-MET inhibitor
9
VEGFR inhibitor, PD-L1 inhibitor
avelumab + axitinib
10
VEGF-A inhibitor, EGFR inhibitor
bevacizumab + erlotinib
11
VEGFR inhibitor
axitinib
12
EGFR inhibitor
erlotinib
13
HIF-2α inhibitor
belzutifan
PT2385
14
ALK inhibitor
crizotinib
alectinib
15
CD70-targeted CAR-T immunotherapy
ALLO-316
atezolizumab
16
PD-L1 inhibitor
avelumab
PD-L1 inhibitor
17
PARP inhibitor
olaparib
18
FGFR inhibitor
ABSK091
19
CDK4 inhibitor, CDK6 inhibitor
palbociclib
20
PD1 inhibitor, IDO1 inhibitor
nivolumab + BMS-986205
pembrolizumab + INCB024360
21
VEGFR-2 inhibitor, c-MET inhibitor
GSK1363089
22
HDAC inhibitor, Multi-tyrosine kinase inhibitor
pazopanib + CG-781
23
VEGF-A inhibitor, PI3Kγ inhibitor, Tubulin inhibitor
bevacizumab + albumin-bound paclitaxel + IPI-549
24
mTORC1 inhibitor, mTORC2 inhibitor
CB-228
25
ALK inhibitor, Multi-tyrosine kinase inhibitor
crizotinib + pazopanib
26
VEGFR inhibitor, mTOR inhibitor
temsirolimus + axitinib
27
BRAF inhibitor
vemurafenib
28
VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
sunitinib
29
FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
lenvatinib
30
pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
sorafenib
31
FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
pembrolizumab + lenvatinib
32
CD122 agonist, IL-2 stimulant
aldesleukin
33
VEGFR-1 inhibitor, VEGFR-2 inhibitor, VEGFR-3 inhibitor
tivozanib
34
FGFR inhibitor, VEGFR inhibitor, RET inhibitor, mTOR inhibitor, c-KIT inhibitor, PDGFR α antagonist
everolimus + lenvatinib
35
PD-L1 inhibitor, VEGF-A inhibitor, PI3Kγ inhibitor
bevacizumab + atezolizumab + IPI-549
36
TIM-1-targeted antibody-drug conjugate, Microtubule inhibitor
CDX-014
37
PD-L1 inhibitor, VEGF-A inhibitor
bevacizumab + atezolizumab
38
PRC2 inhibitor
MRTX2219
39
ATR inhibitor
M6620
40
UCHL1 inhibitor, Androgen receptor inhibitor
enzalutamide capsule + 6RK73
41
RAC1 inhibitor
NSC23766
42
CYP17A1 inhibitor
abiraterone acetate
43
pan-RAF inhibitor, Hyaluronic acid synthase inhibitor, Multi-tyrosine kinase inhibitor
sorafenib + 4-methylumbelliferone
44
DNA synthesis inhibitor
cisplatin
45
TGM2 inhibitor
MD102
46
MEK2 inhibitor, MEK1 inhibitor
U0126
47
Topoisomerase II inhibitor
doxorubicin hydrochloride
48
pan-RAF inhibitor, VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
sorafenib + sunitinib
49
VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
sunitinib + pazopanib
50
PD-L1 inhibitor, VEGF-A inhibitor, PDGFR inhibitor
avelumab + CLS-AX
51
Immunotherapy
Immunotherapy
52
Glutamate inhibitor
Glutamate inhibitor
53
VEGF inhibitor
VEGF inhibitor
54
Tyrosine kinase inhibitor
Tyrosine kinase inhibitor
No biomarker
MET amplification
MET mutation
MET fusion
PD-L1 expression
PD-L1 overexpression
PD-L1 underexpression
PBRM1 mutation
PBRM1 overexpression
PBRM1 deletion
PBRM1 negative
PBRM1 underexpression
KDR rs2071559
KDR C482R
KDR expression
MTOR mutation
FLT1 rs9554320
MTOR Q2223K
FLT1 expression
ROBO3 mutation
AXL-L
ARID1A mutation
AXL overexpression
AXL expression
PD-1 expression
ALK rearrangement
VHL mutation
HGF expression
HGF-L
TSC1 deletion
TSC2 H1620R + TSC2 Y1650C
HMOX1 expression
TSC2 mutation
TSC1 mutation
HMOX1-L
VHL deletion
HGF-H
PD-1-H
VHL promoter methylation
IL6-L
MSI-H/dMMR
BRCA1 mutation
BRCA2 mutation
KIM1 expression
FLCN mutation
TFE3 translocation
HDAC2 expression
ERVE-4 expression
HAVCR2 expression
SPP1-L
CXCL8-L
IL18 expression
ANGPT2 expression
TIMP1 expression
CSF1 expression
VEGFA expression
CXCL9 expression
IL18BP expression
SYNE1 mutation
CDKN2A mutation
CEACAM1 overexpression
CXCL10 overexpression
CA9 expression
CD31 expression
GNAQ mutation
IKZF2-L
KDM5C mutation
PDGFRA expression
CD8 expression
HIF1A expression
LRP1B mutation
ELTD1 expression
BAP1 negative
IL6R L
IL6ST-H
TFEB translocation
EWSR1-POU5F1 fusion
KMT2C mutation
LDH elevation
CTLA4 promoter hypomethylation
NANOGNB mutation
PARP1 underexpression + PBRM1 mutation
PTTG1 overexpression
TNFRSF9 elevation
PD-L1 expression + CD14 positive
LAG3 positive + CD4 positive
TNFRSF9 positive + CD8 positive
TNFRSF9 positive + CD4 positive
NF2 mutation
FH mutation
FOLH1 overexpression
KHDRBS1 overexpression
PBRM1 mutation + SETD2 mutation
TERT promoter mutation
BRAF mutation
miR138 underexpression + miR497 overexpression
SETD2 mutation + TP53 mutation
FLCN deletion
BAP1 mutation
IL6-H
CXCL10-H
TERT overexpression
IL6 elevation
BAP1 deletion
VEGFA-H
SETD2 mutation
CXCL8 elevation
VEGFA elevation
CDKN2A deletion
KIM1 elevation
Tregs-H
DDR
T-cell-inflamed GEP signature
IFNG gene signature overexpression
Chr del(9)(p21.3)
CXCR4 overexpression
PAI1-H
TGM2 overexpression
CXCL12-H
HLA-A*03
PRCC-TFE3 fusion
HAS3 expression
TP53 expression
DAPK1 underexpression
EPAS1 overexpression
MCAM overexpression
PLK1 overexpression
miR-155 underexpression
FGFR1 overexpression
SMARCA4 mutation
LAG3 expression
KDM6A mutation
CCL4 elevation
CXCL11-H
AR-V7 positive
DDX39B overexpression
AXL overexpression + PD-L1 expression
CCNE1 amplification
TP53 mutation
CTBP1 deletion
CXCL13 elevation
TNFSF13B elevation
TMB-H
CD44 expression
CD44 positive
ACRBP amplification
GNAS amplification
LRP10 deletion
IL7 elevation
SULT1A3 amplification
UGT1A9 expression
ADCYAP1 deletion
PTEN deletion
NT5E overexpression
MTA2 overexpression
IL13RA2 overexpression